Latest Breaking News On - Oswald cruz foundation - Page 1 : comparemela.com

PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine usi

United statesRio de janeiroEstado do rioOswaldo cruzRio grande do sulUnited kingdomBio manguinhos fiocruzSotiris missailidisStorme moore thornicroftBrazilian ministry of healthEmergex vaccines holding limitedImmunobiological technology institute bio manguinhosBrazilian national health serviceMinistry of healthHistory of public healthInstitute of technology on immunobiologicals